

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

4427 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

4429 Neopeptides as Difference Makers for General Cancer Vaccines?

Jessica N. Filderman and Walter J. Storkus

See related article, p. 4511

4432 Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer

Taymaa May and Amit M. Oza

See related article, p. 4625

Reviews

4435 Improvements in Clinical Outcomes for *BRAF*^{V600E}-Mutant Metastatic Colorectal Cancer

Van K. Morris and Tanios Bekaii-Saab

4442 The Role of Antigen Spreading in the Efficacy of Immunotherapies

Peter Brossart

Perspectives

4448 Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment-like Conditions

Luke Maggs and Soldano Ferrone

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

4454 Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, and Jonathan Cebon

CLINICAL TRIALS: TARGETED THERAPY

4460 Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

A C Carlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, Caly Chien, Hiroji Uemura, David Olmos, Paul Mainwaring, Ji Youl Lee, Margaret K. Yu, Juan Jose Perez-Ruixo, Matthew R. Smith, and Eric J. Small

4468 A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Singh Cheema, Philip A. Dy, Timothy E. O'Brien, Jane N. Winter, Terrence P. Cescon, Julie E. Chang, and Brad S. Kahl

4478 Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis

Stefano Indraccolo, Gian Luca De Salvo, Martina Verza, Mario Caccese, Giovanni Esposito, Ilaria Piga, Paola Del Bianco, Marco Pizzi, Marina Paola Gardiman, Marica Eoli, Roberta Rudà, Alba Ariela Brandes, Toni Ibrahim, Simona Rizzato, Ivan Lolli, Vittorina Zagonel, and Giuseppe Lombardi

4485 Association of *NOS3* and *ANGPT2* Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri, Luca Faloppi, Paola Ulivi, Francesco Giuseppe Foschi, Emiliano Tamburini, Caterina Vivaldi, Mario Domenico Rizzato, Luca Ielasi, Matteo Canale, Fabio Conti, Britt Rudnas, Lorenzo Fornaro, Nicola Silvestris, Marianna Silletta, Giovanni Gerardo Cardellino, Sara Lonardi, Francesca Fornari, Giulia Orsi, Giulia Rovesti, Vittorina Zagonel, Stefano Cascinu, and Mario Scartozzi

TABLE OF CONTENTS

CLINICAL TRIALS: IMMUNOTHERAPY

- 4494** **Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers**
Soo-Chin Lee, Noriko Shimasaki, Joline S.J. Lim, Andrea Wong, Kritika Yadav, Wei Peng Yong, Lip Kun Tan, Liang Piu Koh, Michelle L.M. Poon, Sing Huang Tan, Samuel G.W. Ow, Lavina Bharwani, Yoon Sim Yap, Mabel Z.Q. Foo, Elaine Coustan-Smith, Raghav Sundar, Hon Lyn Tan, Wan Qin Chong, Nesaretnam Barr Kumarakulasinghe, Jedidah L.M. Lieow, Priscillia J.X. Koe, Boon Cher Goh, and Dario Campana
- 4503** **A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial**
Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, and Magnus von Knebel Doeberitz
- 4511** **A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors**
AC Yong Fang, Fan Mo, Jiawei Shou, Huimin Wang, Kai Luo, Shanshan Zhang, Ning Han, Hongsen Li, Shengli Ye, Zhan Zhou, Rongchang Chen, Lin Chen, Liang Liu, Huina Wang, Hongming Pan, and Shuqing Chen
See related commentary, p. 4429
- 4521** **Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial**
Qian Mei, Wenyong Zhang, Yang Liu, Qingming Yang, John E.J. Rasko, Jing Nie, Jiejie Liu, Xiang Li, Liang Dong, Meixia Chen, Yan Zhang, Lu Shi, Huitao Wu, and Weidong Han
- 4531** **Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study**
AC Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, and David S. Hong
- 4542** **Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma**
AC Jianming Xu, Yuxian Bai, Nong Xu, Enxiao Li, Buhai Wang, Jin Wang, Xiang Li, Xin Wang, and Xianglin Yuan

PRECISION MEDICINE AND IMAGING

- 4551** **A Prospective Trial of ⁶⁸Ga-PSMA and ¹⁸F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration**
Beihe Wang, Chang Liu, Yu Wei, Jin Meng, Yingjian Zhang, Hualei Gan, Xiaoping Xu, Fangning Wan, Jian Pan, Xuejun Ma, Silong Hu, Stephen J. Freedland, Shaoli Song, DingWei Ye, and Yao Zhu
- 4559** **Functional Categorization of *BRCA1* Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays**
Peter Bouwman, Ingrid van der Heijden, Hanneke van der Gulden, Roebi de Bruijn, Merel E. Braspenning, Setareh Moghadas, Lodewyk F.A. Wessels, the Dutch-Belgian VUS workgroup, Maaikje P.G. Vreeswijk, and Jos Jonkers
- 4569** **FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes**
Asmerom T. Sengal, Ann-Marie Patch, Cameron E. Snell, Deborah S. Smith, Samuel C.Y. Leung, Aline Talhouk, Elizabeth D. Williams, Jessica N. McAlpine, and Pamela M. Pollock
- 4581** **Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer**
Nicholas R. Perkins, Omar Johnson, Gabrielle Pilla, Enri Profka, Michael Mercadante, Daniel Ackerman, and Terence P.F. Gade
- 4590** **Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors**
Maddalena Centanni, Sreenath M. Krishnan, and Lena E. Friberg
- 4599** **Population-based Screening for *BRAF*^{V600E} in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis**
Jenny E. Chu, Benny Johnson, Laveniya Kugathasan, Van K. Morris, Kanwal Raghav, Lucas Swanson, Howard J. Lim, Daniel J. Renouf, Sharlene Gill, Robert Wolber, Aly Karsan, Scott Kopetz, David F. Schaeffer, and Jonathan M. Loree
- 4606** **Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer**
Annette Lischka, Natalie Doberstein, Sandra Freitag-Wolf, Ayla Koçak, Timo Gemoll, Kerstin Heselmeyer-Haddad, Thomas Ried, Gert Auer, and Jens K. Habermann

TABLE OF CONTENTS

- 4616** **Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer**
Xiangnan Guan, Duanchen Sun, Eric Lu, Joshua A. Urrutia, Robert Evan Reiter, Matthew Rettig, Christopher P. Evans, Primo Lara Jr, Martin Gleave, Tomasz M. Beer, George V. Thomas, Jiaoti Huang, Rahul R. Aggarwal, David A. Quigley, Adam Foye, William S. Chen, Jack Youngren, Alana S. Weinstein, Joshua M. Stuart, Felix Y. Feng, Eric J. Small, Zheng Xia, and Joshi J. Alumkal

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 4625** **CA-125 ELIMINATION RATE CONSTANT K (KELIM) IS A MARKER OF CHEMOSENSITIVITY IN PATIENTS WITH OVARIAN CANCER: RESULTS FROM THE PHASE II CHIVA TRIAL**
Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwénael Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, and Olivier Colombari
See related commentary, p. 4432

- 4633** **Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alistertib) in Solid Tumors**
S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, and Jennifer R. Diamond

- 4643** **Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617**
Maria Thor, Joseph O. Deasy, Chen Hu, Elizabeth Gore, Voichita Bar-Ad, Clifford Robinson, Matthew Wheatley, Jung Hun Oh, Jeffrey Bogart, Yolanda I. Garces, Vivek S. Kavadi, Samir Narayan, Puneeth Iyengar, Jacob S. Witt, James W. Welsh, Christopher D. Koprowski, James M. Lerner, Ying Xiao, and Jeffrey Bradley

- 4651** **Genomic Profiling of Prostate Cancers from Men with African and European Ancestry**
AC Yusuke Koga, Hanbing Song, Zachary R. Chalmers, Justin Newberg, Eejung Kim, Jian Carrot-Zhang, Daphnee Piou, Paz Polak, Sarki A. Abdulkadir, Elad Ziv, Matthew Meyerson, Garrett M. Frampton, Joshua D. Campbell, and Franklin W. Huang

- 4661** **Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer**
AC Valeria Merz, Camilla Zecchetto, Raffaella Santoro, Francesca Simionato, Fabio Sabbadini, Domenico Mangiameli, Geny Piro, Alessandro Cavaliere, Michela Deiana, Maria Teresa Valenti, Diana Bazan, Vita Fedele, Sara Lonardi, and Davide Melisi

- 4670** **Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and α PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer**
Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, and Zachary C. Hartman

- 4682** **Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer**
Ivana Sestak, Martin Filipits, Richard Buus, Margaretha Rudas, Marija Balic, Michael Knauer, Ralf Kronenwett, Florian Fitzal, Jack Cuzick, Michael Gnant, Richard Greil, Mitch Dowsett, and Peter Dubsy

- 4688** **Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma**
Ester Lozano, Mari-Pau Mena, Tania Díaz, Beatriz Martin-Antonio, Sheila León, Luis-Gerardo Rodríguez-Lobato, Aina Oliver-Caldés, Maria Teresa Cibeira, Joan Bladé, Aleix Prat, Laura Rosiñol, and Carlos Fernández de Larrea


- 4699** **Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells**
AC Ganesh Rao, Khatri Latha, Martina Ott, Aria Sabbagh, Anantha Marisetty, Xiaoyang Ling, Daniel Zamler, Tiffany A. Doucette, Yuhui Yang, Ling-Yuan Kong, Jun Wei, Gregory N. Fuller, Fernando Benavides, Adam M. Sonabend, James Long, Shulin Li, Michael Curran, and Amy B. Heimberger

AC AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

The cover shows a hematoxylin- and eosin-stained microscopic image of a breast tumor biopsy post NK cell therapy. Aggregates of immune cells composed predominantly of lymphocytes, few plasma cells, and macrophages can be seen infiltrating the fibrocollagenous stroma surrounding the nests of tumor cells. For details, see the article by Lee and colleagues on page 4494 of this issue.



Clinical Cancer Research

26 (17)

Clin Cancer Res 2020;26:4427-4712.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/17>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/17>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.